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morbidities and cancers are increasing
in HIV-positive individuals because of
improved prognosis of HIV infection
and high prevalence of smoking. More
effective smoking cessation programs
are therefore needed.1–3 Evidence from
interventional trials indicates that self-
monitoring techniques and motivational
support by mobile phone-based text
messaging may increase quit rates in
smokers.4,5 Self-monitoring of exhaled
carbon monoxide (CO) measurement is
a novel approach that may assist moti-
vated smokers to quit.
We investigated whether CO self-
monitoring in conjunction with a smoking
cessation app may improve smoking
cessation in HIV-positive smokers. We
nested a randomized controlled into the
Swiss HIV Cohort Study,6 and randomly
allocated during biannual cohort visits
patients smoking $3 cigarettes a day
via a trial website to counselling by SHCS
center physicians (usual care) or to a com-
bined intervention of CO self-monitoring
with mobile phone-based feedback and
app-based smoking cessation support. All
participants had to provide informed
consent to trial participation and fix a quit
date within a 2-week period from the
randomization date. All trial participants
irrespective of randomization received
standard smoking cessation care consist-
ing of short smoking cessation advices by
treating center physicians, voluntary refer-
ral to smoking cessation clinics, and
nicotine replacement therapy at
physician discretion.
Study nurses assisted patients in
the intervention group to download the
Smokerlzyer and Stop-tabak apps
(www.stop-tabak.ch) on their personal
mobile phones and assured the patient’s
registration via a secured channel in the
patient communication platform (Jay-
mob; Jackson Mobile Berlin GmbH,
Berlin, Germany), which allowed to
activate the iCO Smokerlyzer commu-
nication mode. The platform allowed to
monitor all CO measurement in a web-
server that was hosted in a T-system
cloud environment and to send reminder
messages for CO measurements. The IT
company provided regular downloads
by patient ID with the CO measurement,
the corresponding dates, and the dates of
sent text reminders, which were trans-
ferred to a secured trial database on the
server of the University Hospital Basel.
Patients were instructed how to
connect the iCO Smokerlyzer (Bedfont
Scientific Ltd, Harrietsham, England)
CO monitoring device with their mobile
phone and how to measure the CO
content in exhaled air. The iCO Smoker-
lyzer is a breath test CO monitor with
a replaceable mouth cap intended for
single users and serves as a motivational
tool to encourage smoking cessation. It
connects via a USB or headphone plug-
in connector to newer generation mobile
phones and measures the CO content in
the exhaled air. Instant readings are
downloaded via app to a personal profile
on the phone. Depending on the results
of the breath test, individualized mes-
sages are delivered to enhance
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maintenance of abstinence or increase
the motivation to quit. Trial participants
received text messages with a request to
use the personal CO monitor Smoker-
lyzer daily for the first 4 weeks, twice
weekly for the following 4 weeks and
once weekly from the beginning of the
third month to the end of the trial.
The Stop-tabac.ch app provides
advices in all Swiss national languages
and English for quitting, coping with
withdrawal symptoms, and relapses and
is supported by the Swiss Ministry of
Health7 and was used and a supplemen-
tary intervention tool in this trial. It
offers a coaching function where users
receive personalized messages that
encourage smoking cessation and give
advice for behavioral change. The app
offers also options to seek support from
friends and family and a forum for
discussing smoking cessation-related is-
sues with peers.
By virtue of the nested trial design,
all demographic and clinical baseline data
and self-reported smoking data relevant
to this trial at baseline and 6 months
follow-up were collected via routinely
biannual cohort visits.6 The primary out-
come was the combination of self-
reported continuous abstinence biochemi-
cally verified at 6 months by an in-person
CO, with a cut-off of CO in exhaled air
of 7 ppm (piCO Smokerlyzer CO, Bed-
font Scientific Ltd) that was done by
nurses not blinded for treatment status.
Self-reported continuous abstinence was
defined as no more than 5 cigarettes
smoked since the start of the abstinence
period at 6 months of follow-up. The
follow-up examination coincided with
the next cohort visit. Self-reported con-
tinuous abstinence was assessed by
physicians during routine 6-month
follow-up and directly entered into the
study’s website. Participants reporting
abstinence whose final CO test was
positive were counted as smokers as were
patients with loss of smoking status
follow-up information. Secondary out-
comes were differences in the number
of daily cigarettes smoked from baseline
to 6-month follow-up and point preva-
lence of abstinence (ie, no smoking in the
past 7 days) at 6-month follow-up.
Based on self-reported quit rates
from users of the Stop-tabab.ch app (8%),
we assumed that our combined intervention
with additional CO self-monitoring would
lead to a six months quit rate of 12% and
5% in the intervention and control groups,
respectively. With a significance level of a
= 0.05 (two-sided) and a power of 0.8,
a total of 496 patients were needed.
The primary intention to treat anal-
ysis was performed on the basis of a self-
reported continuous abstinence (defined
as no more than 5 cigarettes since the
start of the abstinence period) biochemi-
cally verified by a CO breath test at 6
months of follow-up. Patients with miss-
ing data or a positive CO breath test at 6
months of follow-up were counted as
smokers. Analysis was by logistic and
linear regression for smoking cessation
rates and difference in daily cigarette
consumption at 6 months of follow-up,
respectively with adjustment for past self-
reported history of smoking cessation,
numbers of cigarettes smoked at trial
start, and prescribed nicotine replacement
or drugs against withdrawal symptoms.
All analyses were done in R version
3.5.2. The trial protocol was approved
by Swiss Ethics and registered at
ClinicalTrials.gov, ID NCT02840513.
At the start of the trial on June 1,
2017, 3293 of 10,493 (34%) patients in
the SHCS smoked $3 cigarettes and
these 2444 (74%) indicated at any cohort
visit in the previous 48 months to have
quit once and then resumed smoking.
During a recruitment period of 1.5 years,
FIGURE 1. Trial profile.
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1807 patients were screened for inclusion
and a total of 81 patients were enrolled
(Fig. 1). Trial participants compared with
the remaining smoking population in the
SHCS were better educated, had more
previous quit attempts, smoked more
cigarettes, and were more frequently
men having sex with men, but less
frequently IV drug users (Table 1). Six
of 42 (14%) participants in the interven-
tion group and 5 of 39 (13%) in the
standard of care group quit smoking at 6
months follow-up (adjusted odds ratio
1.06, 95% CI: 0.29 to +3.86) and 3
participant were lost to follow-up. Based
on the 12-month cohort data, one indi-
vidual had resumed smoking and 5 trial
participants reported to have quit smok-
ing. The adjusted mean difference in
smoked cigarettes between the interven-
tion and control groups at 6 months was
−1.38 (95% CI: −4.45 to 1.69).
In total, 24 (57%) and 18 (46%)
patients in the intervention and control
groups received nicotine replacement
therapy. Eleven (26%) of the partici-
pants in the intervention group sent at
least one result of a CO measurement
with the Smokerlyzer App (median 22.5
[IQR 6–63]). Twelve (28.5%) partici-
pants in the intervention group reported
using the Stop-tabac.ch app multiple
times a week during the first month of
the intervention. Of all the remaining
smokers in the cohort who did not
participate in the trial, 53 (1.6%) had
reported during the trial recruitment
period not to be smoking at the next 6
months cohort visit and 78 (2.4%) at the
12 months visit. The trial was terminated
prematurely because of insufficient
patient recruitment and lack of funding.
Results from this pragmatic trial
remained inconclusive and underpow-
ered because of recruitment difficulties,
although the nested trial design allowed
for the potential to recruit from a large
group of smokers with a self-reported
history for quitting. Patients included in
the trial reported more cessation at-
tempts than nonparticipants, which was
identified as the best predictor for suc-
cessful quitting from observational data
analysis of the SHCS.8 This information,
however, did not translate into a high
recruitment rate. Forcing patients to fix
a quit date in a time window of 2 weeks
after the cohort visit may have dis-
tracted, not optimally motivated patients
ready to immediately try to quit. Instal-
lation of smoking cessation and CO
monitoring apps was time consuming
and many patients indicated difficulties
in using the CO monitoring device. The
high variety of mobile phone models
and operating systems created compati-
bility problems with the CO device,
some of which were hard to identify
during the initial setup and installation.
Integrating this intervention into the
routine of busy infectious disease clinics
turned out to be very demanding for
clinicians and staff. Nevertheless, 11%
of the trial population—irrespective of
the intervention—quit, which is
TABLE 1. Baseline Characteristics of Trial Participants and of the Entire Smoking Population in the Swiss HIV Cohort Study
Trial Participants Intervention Control Smokers in Cohort
Randomized to trial/entire cohort (n) 81 42 39 3293
Males (n, %) 68 (84%) 36 (86%) 32 (82%) 2489 (76%)
Age (median [IQR]) 47 (40–52) 47.5 (41–52) 47 (40–52) 50 (42–550)
Education $9 years (n, %) 62 (77%) 31 (74%) 31 (80%) 2338 (74%)*
Pack years (median [IQR]) 15 (9–25) 15 (9–26) 16 (7.5–24) 18 (10–25)†
Cigarettes smoked (median [IQR]) 17 (10–20) 15.5 (10–20) 20 (10–20) 15 (10–20)
Previous attempt to quit smoking (n, %) 23 (28%) 12 (29%) 11 (28%) 695 (21%)
Framingham risk score
,10% 48 (59%) 25 (59.5%) 23 (59%) 1855 (56.3%)
10%–19% 25 (31%) 14 (33.3%) 11 (28%) 985 (30%)
.20% 6 (7.5%) 2 (4.8%) 4 (10%) 449 (13.6%)
Missing 2 (2.5%) 1 (2.4%) 1 (3%) 4 (0.1%)
Previous CV event (n, %) 10 (12%) 7 (17%) 3 (7.7%) 301 (9.1%)
On ART (n, %) 81 (100%) 402 (100%) 39 (100%) 3169 (96%)‡
Previous AIDS event (n, %) 14 (17%) 6 (14%) 8 (21%) 721 (22%)
CD4 start cells/mL (median [IQR]) 732 (540–960) 754 (537–975) 696 (556–936) 704 (507–926)§
RNA viral load .20 copies/mL (n, %) 8 (10%) 3 (7%) 5 (13%) 321 (10%)¶
RNA viral load .400 copies/mL (n, %) 2 (2.5%) 1 (2.6%) 1 (2.4%) 98 (3%)
Current IV drug use (n, %) 7 (9%) 3 (7%) 4 (10%) 359 (10.9%)
Source of infection (n, %)
Men having sex with men 41 (51%) 22 (52%) 19 (49%) 1433 (44%)
Heterosexual 27 (33%) 16 (38%) 11 (28%) 983 (30%)
Intravenous drug use 9 (11%) 2 (5%) 7 (18%) 732 (22%)
Other sources 4 (5%) 2 (5%) 2 (5%) 145 (4%)
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considerably higher than the 1.6%
smokers in the remaining cohort who
had indicated to have quit.
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